Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
NCT03315130 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG zilucoplan (RA101495)
Study Locations (20)
California
- The Research Center of Southern California — Carlsbad
- UCLA Medical Center — Los Angeles
- University of California Irvine Health ALS and Neuromuscular Center — Orange
New York
- University of Buffalo — Buffalo
- Hospital for Special Surgery — New York
- Mount Sinai Hospital — New York
Florida
- University of Florida — Jacksonville
- University of South Florida — Tampa
Massachusetts
- Massachusetts General Hospital — Boston
- Lahey Hospital and Medical Center — Burlington
Michigan
- Wayne State University — Detroit
- Michigan State University — East Lansing
Alabama
- Diagnostic and Medical Clinic - Mobile — Mobile
Connecticut
- Yale University — New Haven
District of Columbia
- George Washington University — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2020-11-19 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315130
The ClinicalTrials.gov registry entry for NCT03315130 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ra Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Generalized Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03315130 reports 20 study locations spanning 13 distinct geographic areas — top geographies include California, New York, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03315130 about?
NCT03315130 is a clinical study titled "Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis". The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.
What is the current status of trial NCT03315130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2017-10-11. Estimated completion is 2020-11-19.
What conditions does trial NCT03315130 study?
This clinical trial studies the following conditions: Generalized Myasthenia Gravis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03315130?
The interventions under investigation include: Placebo (DRUG), zilucoplan (RA101495) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03315130?
This trial is sponsored by Ra Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03315130 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.